

## **Reviva to Present at the UBS Virtual CNS Day**

CUPERTINO, Calif., March 11, 2024 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a Fireside Chat at the UBS Virtual CNS Day, taking place virtually March 18, 2024.

### **UBS Virtual CNS Day**

Format: Fireside Chat

Date: Monday, March 18, 2024

Time: 1:30 p.m. ET

Location: Virtual

To register for the event, please [click here](#) or contact your UBS representative.

### **About Reviva**

Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system, respiratory and metabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.

### **Corporate Contact:**

Reviva Pharmaceuticals Holdings, Inc.

Laxminarayan Bhat, PhD

[www.revivapharma.com](http://www.revivapharma.com)

### **Investor Relations Contact:**

LifeSci Advisors, LLC

Bruce Mackle

[bmackle@lifesciadvisors.com](mailto:bmackle@lifesciadvisors.com)

### **Media Contact:**

Kristin Politi

[kpoliti@lifescicomms.com](mailto:kpoliti@lifescicomms.com)

(646) 876-4783

